Novartis' SMA gene-therapy, if priced at $2M, could be more cost-effective than Biogen's Spinraza — ICER
Biogen’s Spinraza was approved by the FDA amidst much fanfare in 2016 as the first and only disease-modifying treatment for SMA, a rare and often fatal genetic muscular disorder. But the price tag of $750,000 for the first year of therapy (and a lower price thereafter) prompted heavy criticism, although many payers eventually agreed to reimburse the treatment. However, a report by the Institute for Clinical and Economic Review (ICER) on Thursday has suggested Novartis’ experimental SMA gene therapy, Zolgensma, could be more cost-effective in the long run versus Spinraza.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
